The aim of the present manuscript is to provide an overview of the most updated studies on the prevalence of primary aldosteronism in primary care and to compare these figures with the actual rate of diagnosis in clinical practice and with the prevalence of primary aldosteronism in specific subgroup of patients.
INTRODUCTION
The 2016 Lancet commission on hypertension highlighted that missing a diagnosis of secondary hypertension is one of the most important reasons for the unacceptably low control rate of blood pressure (BP) levels in patients with hypertension [1] . Although the 2016 Endocrine Society guideline suggests screening for primary aldosteronism all patients with hypertension and high risk of primary aldosteronism [2 && ], which account for more than half of the hypertensive population, the diagnosis of primary aldosteronism is still largely inadequate [3 & ].
Recently, the primary aldosteronism in Torino study reported a primary aldosteronism prevalence of about 6% in a large cohort of unselected patients with hypertension referred by general practitioners. Primary aldosteronism prevalence increased with the severity of hypertension, but notably 44% of the identified cases were affected by stage I hypertension (that is SBP level comprised between 140 and 160 mmHg and/or DBP levels comprised between 90 and 100 mmHg) [4 & ]. These data are particularly relevant for the observed significant association between primary aldosteronism and a higher risk of cerebro and cardiovascular events, cardiac organ damage, and metabolic comorbidities compared with patients with essential hypertension, independent of BP levels [5 & ]. In fact, the identification of patients with primary aldosteronism and a correct subtype diagnosis are important to offer a prompt and specific treatment (surgical cure or targeted pharmacotherapy) which has been demonstrated not only to significantly improve BP and correct electrolyte abnormalities [6
&& ], but even to revert target organ damage [8, 9] and reduce the cardiovascular associated risk [7 && ].
Over the last 25 years many studies investigated the prevalence of primary aldosteronism in primary care settings and in referral centers. Although diagnostic criteria varied widely between different studies, especially in those performed before the publication of the first Endocrine Society Guideline in 2008 [10] , a median primary aldosteronism prevalence of around 6% in primary care setting and 11% in referral centers is observed [11] . Prevalence of primary aldosteronism in primary care progressively increases with the severity of hypertension, from 2-4% in mildest forms to 12-13% in the most severe forms, [4 & ,12] and from 7% in mildest forms to 19% in the most severe in referral centers [13] . In patients with resistant hypertension, primary aldosteronism reaches its highest prevalence (up to 20%) [14] .
A correct subtype diagnosis allows the identification of an aldosterone-producing adenoma (APA) in one-third of primary aldosteronism cases and bilateral adrenal hyperplasia in the remaining patients [16] .
Primary aldosteronism seems to be more prevalent in some specific subgroups, such as patients with hypertension and obstructive sleep apnoea syndrome [17] : for this reason, the 2016 Guideline recommends that primary aldosteronism screening should be extended also to this category of patients [2 && ]. The association between primary aldosteronism and a higher risk of developing type 2 diabetes was historically described by Conn [18] and recently confirmed in a cross-sectional meta-analysis [5 & ]. However, it is not yet established if patients with type 2 diabetes should be systematically screened for primary aldosteronism or only patients with concomitant severe hypertension, in which a high prevalence was observed [19] .
Finally, patients with primary aldosteronism have a higher risk of atrial fibrillation [5 ] . No prospective studies have investigated the prevalence of primary aldosteronism in patients with atrial fibrillation; an ongoing study in patients with lone atrial fibrillation will provide more information in the near future [20] . If the prevalence of primary aldosteronism is 5% and a prevalence of hypertension among adults is 20-30%, the prevalence of primary aldosteronism should be 1-1.5% in the general population. However, recent analysis performed in Italy and Island showed an estimated prevalence of primary aldosteronism from
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KEY POINTS
Recent studies reported a prevalence of primary aldosteronism of about 6% among unselected patients with arterial hypertension, with the highest percentage in patients with the most severe degrees of hypertension, but with a not negligible rate even in patients with mild hypertension.
Among Italian and German general practitioners, primary aldosteronism is investigated in less than 20% of the expected patients according to the recommendations of the Endocrine Society guideline.
Analysis of hospital registries demonstrated unacceptably low rates of diagnosis of primary aldosteronism compared with the expected prevalence and even lower rates of adrenalectomies compared with the expected rate of diagnosis of unilateral forms of primary aldosteronism.
The prevalence of primary aldosteronism among individuals with normal BP levels and normokalemia is relatively high and, among individuals with normotension, high aldosterone levels predict a high risk of developing hypertension, especially in the presence of low renin levels.
hospital registry between 1.0 and 2.2/10 000 individuals [21] [22] . Patients with a diagnosis of primary aldosteronism in an ambulatory setting and who did not undergo a subtype diagnosis with adrenal venous sampling or those who had a surgical adrenalectomy are probably missed by this kind of registries. Nevertheless, even if we consider that patients with milder primary aldosteronism are probably missed, the figures reported are much lower than expected.
Hypokalemia was present in 53-100% of patients with primary aldosteronism recorded in European hospital registries [22] [23] [24] and this probably reflects a selection for the most severe cases of primary aldosteronism and a low rate of diagnosis of milder forms. A national survey performed in Japan in 2014 demonstrated unilateral forms of primary aldosteronism in more than two-thirds of cases [25] . As it is known that patients with APAs display a more severe phenotype compared with patients with bilateral adrenal hyperplasia [4 & ], it is probable that even in Asia, milder forms of primary aldosteronism are largely underdiagnosed.
As one-third of patients with primary aldosteronism have a unilateral form, which benefit from unilateral adrenalectomy [6 & ], if we consider that 1-2% of individuals in general population have a new diagnosis of hypertension each year, we would expect that the number of adrenalectomies should be 2-4/ 10 000 patients/year. However, the number of adrenalectomies performed for primary aldosteronism in an Italian hospital registry was much lower (1.0% of expected adrenalectomies in the period 2000-2015 in the Italian region of Emilia Romagna).
PREVALENCE OF PRIMARY ALDOSTERONISM AMONG INDIVIDUALS WITHOUT HYPERTENSION
Only few studies have evaluated the primary aldosteronism prevalence among individuals with normal BP levels. The first case of primary aldosteronism with normotension and hypokalemia was described in 1972 in a patient with aldosterone-producing carcinoma; subsequently, almost 30 cases of primary aldosteronism diagnosed in patients without hypertension have been reported in the scientific literature [26] . Hypokalemia was the hallmark of all cases and most patients were symptomatic, female, and relatively young, suggesting that age and sex may play a protective role in the hemodynamic effects mediated by aldosterone excess [27] .
In 2011, Ito et al. [28] screened for primary aldosteronism in 44 patients with prehypertension and normal potassium serum level, demonstrating a relatively high prevalence of primary aldosteronism (6.8%). Two of the three patients with confirmed primary aldosteronism showed a unilateral form of primary aldosteronism and after unilateral adrenalectomy displayed a reduction of BP levels. A recent study observed a lower prevalence of primary aldosteronism (1.8%) [29] . However, only 17% of patients with a positive screening test underwent a confirmatory test, suggesting that the real primary aldosteronism prevalence was likely higher than reported.
Other studies investigated the prevalence of aldosterone overproduction, beyond the strict criteria of primary aldosteronism diagnosis, identifying a prevalence of 13-14% of patients with unsuppressible aldosterone secretion [30, 31] . Markou et al. [30] used, as confirmatory test, a slightly modified version of the fludrocortisone suppression test, with different cut-off criteria compared to the Endocrine Society Guideline [2 && ] and with administration of oral dexamethasone to reduce the effect of adrenocortical tropic hormone on aldosterone secretion. Instead, Baudrand et al. [31] , performed the oral sodium-loading test in all patients with low plasma renin activity levels, independent of a positive plasma aldosterone/renin ratio at basal values.
Although genetic forms of primary aldosteronism are usually associated with a severe phenotype, in some kindreds with familial hyperaldosteronism patients with the diagnosis of primary aldosteronism and normotension have been reported [32] [33] [34] [35] .
RENIN-INDEPENDENT AND SUBCLINICAL ALDOSTERONISM
Recent developments on the pathophysiology and molecular basis of aldosterone overproduction and the study of the subclinical phase of autonomous aldosterone production, allowed the broadening of the spectrum of low-renin conditions. Brown et al. [36 && ], in a prospective longitudinal study, recently demonstrated that individuals with normal BP levels and suppressed renin activity, display a higher risk of developing hypertension. Furthermore, only in study participants with suppressed renin, high aldosterone levels were associated with a higher risk of incident hypertension [36 && ]. These data are in agreement with the analysis of the Framingham Offspring Study that demonstrated an association between aldosterone levels and the development of hypertension in patients with normal BP levels [37, 38] .
The progressive increase of aldosterone secretion, until its production becomes independent of renin regulation, results in normotensive aldosteronism. Patients with normotensive aldosteronism display a more than 15-fold higher risk of developing hypertension than controls without primary aldosteronism [30] .
Aldosterone levels are not detrimental per se: in a context of sodium deficiency, high aldosterone levels are part of a homeostatic balance and do not increase the risk of aldosterone-associated cardiovascular damage. On the other hand, high aldosterone levels in the presence of high-salt diet are inappropriate and not 'homeostatic,' leading to higher incidence of hypertension and cardiovascular damage [5 & ,39] . In this context a potential significant role may be played by endogenous ouabain. Endogenous ouabain is a hormone secreted by the adrenal cortex under the regulation of adrenocortical tropic hormone, angiotensin-II (via angiotensin receptor type 2), and sodium loading [40] [41] [42] . Endogenous ouabain induces vasoconstriction with consequent increase of vascular resistance and BP levels, and increases natriuresis [43] . When aldosterone levels are appropriately high, such as in conditions of sodium deficiency, sodium balance is preserved and endogenous ouabain is not increased. By contrast, when aldosterone is inappropriately high, the excessive sodium retention causes an increase of endogenous ouabain secretion by adrenal cortex with consequent further increase in BP levels [39] . These observations explain the different predictive role of aldosterone levels observed in the study of Brown et al. [36 && ]. In a condition of renin-independent aldosteronism the homeostatic balance is lost and the sodium load is excessive, leading to increase of endogenous ouabain with consequent development of hypertension. This is not the case for condition in which aldosterone is physiologically regulated by the renin-angiotensin system.
The recent description of the aldosterone-producing cell clusters (APCCs) provided a potential basis for the renin-independent aldosterone production. APCCs are clusters of subcapsular zona glomerulosa-like cells and inner zona fasciculata-like cells of 0.2-1.5 mm of diameter which express aldosterone synthase (CYP11B2), but not 11b-hydroxylase (involved in the last step of cortisol synthesis) [44, 45] .
Recent studies demonstrated that APCCs are relatively frequent even in the adrenal glands removed from patients with normal BP levels [46] . In particular, aging is associated with a decrease in CYP11B2 expression in the normal zona glomerulosa and concomitant increase in APCCs, explaining the common finding of a progressive reduction of renin level with age and relative increase of aldosterone levels [47 && ]. Some APCCs harbor the same mutations associated with autonomous aldosterone production in APAs [48] [49] [50] , suggesting that they could be considered as precursors of some types of APAs [51] . These observations underline the importance of an early diagnosis and treatment of primary aldosteronism. The high prevalence of this condition, even in the general hypertensive population and in patients with a mild hypertensive phenotype, point toward the necessity of widening the number of patients with hypertension that should be screened early for primary aldosteronism. Unfortunately, the vast majority of patients with primary aldosteronism, and particularly the mildest forms, will remain undiagnosed. Therefore, although robust data from prospective randomized trials on the most appropriate treatment in patients with low renin hypertension without a confirmed diagnosis of primary aldosteronism are currently lacking, the use of specific drugs that block aldosterone effects in those patients could prevent the cardiometabolic effects of an excessive aldosterone production and should be considered in the early steps of pharmacological treatment. The authors reported a rate of biochemical success after adrenalectomy in patients with a unilateral form of primary aldosteronism of 94% and a rate of complete or partial clinical success in more than 80% of adrenalectomies in a large, multicenter cohort.
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Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2017; 6:51-59. The retrospective cohort study demonstrated that primary aldosteronism patients treated with mineralocorticoid receptor (MR) antagonists are exposed to an increased risk of incident cardiometabolic events and death compared with age-matched patients with essential hypertension. The excess risk was limited to patients with persistent suppressed renin activity despite MR treatment.
